This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: Test the hypothesis that Fragmin (dalteparin sodium) 200 units/kg subcutaneously given at the time of presentation followed by 10,000 units given subcutaneously once daily for 6 days is more effective that Ibuprofen 800mg given orally three times daily for 7 days for the treatment of superficial thrombophlebitis.
Specific Aims 1. To evaluate the incidence of extension of superficial thrombophlebitis by ultrasound imaging in patients treated with dalteparin 200 units/kg at presentation followed by 10,000 units subcutaneously (sc) once daily or Ibuprofen 800mg orally three times daily. 2. To evaluate the degree of pain resolution while taking the prescribed medication. 3. To evaluate the risk of bleeding associated with the treatments. 4. To gather descriptive/demographic data on patients with superficial thrombophlebitis. 5. To perform a pharmacoeconomic assessment of treatment of superficial thrombophlebitis using low molecular weight heparin (Fragmin) versus oral ibuprofen.
Showing the most recent 10 out of 209 publications
